CareDx agreed to acquire Naveris for up to $260 million in a move to expand its oncology diagnostics footprint. The deal structure includes $160 million upfront plus up to $100 million in revenue-based milestones. CareDx said it will gain access to NavDx, a liquid biopsy test that measures tumor-naïve minimal residual disease through circulating HPV-driven DNA fragments. NavDx received Medicare coverage in 2023, and CareDx expects Naveris revenue to grow 30% to 40% annually over the next three years. The company positioned the acquisition as targeted rather than a broad pivot into MRD across all cancers, citing the reimbursement and specialty workflow fit for viral-mediated tumor monitoring. The transaction also signals continued consolidation in oncology diagnostics, with acquirers focusing on tests embedded in existing clinical reimbursement frameworks.